Neurocrine Biosciences, Inc. (NBIX)
Pre-market:
| Previous close | 133.23 |
| Open | 133.23 |
| Bid | 132.38 x 100 |
| Ask | 132.64 x 100 |
| Day's range | 131.51 - 134.15 |
| 52-week range | 89.04 - 148.37 |
| Volume | |
| Avg. volume | 872,550 |
| Market cap | 13.331B |
| Beta (5Y monthly) | 0.28 |
| PE ratio (TTM) | 53.66 |
| EPS (TTM) | 2.47 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 151.96 |
- GlobeNewswire
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Sentia Medical Sciences Inc. today announced that they have further extended a research collaboration with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) aimed at discovering novel, long-acting corticotropin-releasing factor (CRF) receptor antagonist peptide therapeutics. The collaboration will continue to leverage Sentia’s proprietary peptide-based platform and Neurocrine’s drug development expertise in CRF biology to develop and commercialize medicine
PR NewswireNeurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on May 1, 2024.
Insider Monkey11 Best Biotech ETFs To Buy
In this article, we discuss 11 best biotech ETFs to buy. If you want to skip our discussion on the biotech industry, head over to 5 Best Biotech ETFs To Buy. The new era in biotech is defined by the convergence of biology, data, and artificial intelligence. According to The Journal of mHealth, the focus […]
